BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU). Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int 2019;39:20-30. [PMID: 30157316 DOI: 10.1111/liv.13949] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Martínez I, Ryan P, Valencia J, Resino S. The Challenging Road to Hepatitis C Virus Eradication. J Clin Med 2021;10:611. [PMID: 33562818 DOI: 10.3390/jcm10040611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Maughan A, Sadigh K, Angulo-Diaz V, Mandimika C, Villanueva M, Lim JK, Ogbuagu O. Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients. BMC Infect Dis 2019;19:378. [PMID: 31053098 DOI: 10.1186/s12879-019-3974-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Grebely J, Collins AB, Artenie AA, Sutherland R, Meyer JP, Barocas JA, Falade-Nwulia O, Cepeda JA, Cunningham EB, Hajarizadeh B, Lafferty L, Lazarus JV, Bonn M, Marshall AD, Treloar C. Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. Int J Drug Policy 2021;96:103469. [PMID: 34610884 DOI: 10.1016/j.drugpo.2021.103469] [Reference Citation Analysis]
4 Akiyama MJ, Lipsey D, Heo M, Agyemang L, Norton BL, Hidalgo J, Lora K, Litwin AH. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy. Clin Infect Dis 2020;70:2695-702. [PMID: 31346609 DOI: 10.1093/cid/ciz693] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 19.0] [Reference Citation Analysis]
5 Lazarus JV, Mark HE, Colombo M, Demaio S, Dillon JF, George J, Hagström H, Hocking S, Lee N, Nieuwenhuijsen MJ, Rinella ME, Romero-Gomez M, Soriano JB, Schattenberg JM, Tacke F, Tsochatzis EA, Valenti L, Zelber-Sagi S, Ashworth Dirac M, Huang TT. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Aliment Pharmacol Ther 2021. [PMID: 34866201 DOI: 10.1111/apt.16720] [Reference Citation Analysis]
6 Velosa J, Macedo G. Elimination of Hepatitis C in Portugal: An Urban Legend? GE Port J Gastroenterol 2020;27:166-71. [PMID: 32509922 DOI: 10.1159/000505582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Fernández de Cañete Camacho JC, Mancebo Martínez A, García Mena MA, Moreno Planas JM. Influence of psychiatric disorders and opioid substitution therapy on hepatitis C treatment with direct-acting antivirals in people who inject drugs. Gastroenterol Hepatol 2021:S0210-5705(21)00251-X. [PMID: 34543719 DOI: 10.1016/j.gastrohep.2021.09.003] [Reference Citation Analysis]
8 Olafsson S, Fridriksdottir RH, Love TJ, Tyrfingsson T, Runarsdottir V, Hansdottir I, Bergmann OM, Björnsson ES, Johannsson B, Sigurdardottir B, Löve A, Baldvinsdottir GE, Hernandez UB, Gudnason T, Heimisdottir M, Hellard M, Gottfredsson M. Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study. Lancet Gastroenterol Hepatol 2021;6:628-37. [PMID: 34171267 DOI: 10.1016/S2468-1253(21)00137-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Øvrehus ALH, Midgard H. How can we achieve WHO's elimination target for hepatitis C incidence? Lancet Gastroenterol Hepatol 2019;4:415-7. [PMID: 30981687 DOI: 10.1016/S2468-1253(19)30120-7] [Reference Citation Analysis]
10 Larney S, Tran LT, Leung J, Santo T Jr, Santomauro D, Hickman M, Peacock A, Stockings E, Degenhardt L. All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids: A Systematic Review and Meta-analysis. JAMA Psychiatry 2020;77:493-502. [PMID: 31876906 DOI: 10.1001/jamapsychiatry.2019.4170] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
11 Walker S, Wallace J, Latham N, Saich F, Pedrana A, Hellard M, Treloar C, Marukutira T, Higgs P, Doyle J, Stoové M. "It's time!": A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C. Int J Drug Policy 2021;97:103280. [PMID: 34058670 DOI: 10.1016/j.drugpo.2021.103280] [Reference Citation Analysis]
12 Metsch LR, Feaster DJ, Gooden LK, Masson C, Perlman DC, Jain MK, Matheson T, Nelson CM, Jacobs P, Tross S, Haynes L, Lucas GM, Colasanti JA, Rodriguez A, Drainoni ML, Osorio G, Nijhawan AE, Jacobson JM, Sullivan M, Metzger D, Vergara-Rodriguez P, Lubelchek R, Duan R, Batycki JN, Matthews AG, Munoz F, Jelstrom E, Mandler R, Del Rio C. Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064). Open Forum Infect Dis 2021;8:ofab334. [PMID: 34377726 DOI: 10.1093/ofid/ofab334] [Reference Citation Analysis]
13 Monroe-Wise A, Mbogo L, Guthrie B, Bukusi D, Sambai B, Chohan B, Scott J, Cherutich P, Musyoki H, Bosire R, Dunbar M, Macharia P, Masyuko S, Wilkinson E, De Oliveira T, Ludwig-Barron N, Sinkele B, Herbeck J, Farquhar C. Peer-mediated HIV assisted partner services to identify and link to care HIV-positive and HCV-positive people who inject drugs: a cohort study protocol. BMJ Open 2021;11:e041083. [PMID: 33895711 DOI: 10.1136/bmjopen-2020-041083] [Reference Citation Analysis]
14 Mafirakureva N, Stone J, Fraser H, Nzomukunda Y, Maina A, Thiong'o AW, Kizito KW, Mucara EWK, González Diaz CI, Musyoki H, Mundia B, Cherutich P, Nyakowa M, Lizcano J, Chhun N, Kurth A, Akiyama MJ, Waruiru W, Bhattacharjee P, Cleland C, Donchuk D, Luhmann N, Loarec A, Maman D, Walker J, Vickerman P. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis. Addiction 2022;117:411-24. [PMID: 34184794 DOI: 10.1111/add.15630] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Øvrehus A, Kåberg M. HCV treatment for people with recent drug use: time for new measures of success? Lancet Gastroenterol Hepatol 2018;3:731-2. [PMID: 30245063 DOI: 10.1016/S2468-1253(18)30307-8] [Reference Citation Analysis]
16 Litwin AH, Jost J, Wagner K, Heo M, Karasz A, Feinberg J, Kim AY, Lum PJ, Mehta SH, Taylor LE, Tsui JI, Pericot-Valverde I, Page K; HERO Study Group. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. Contemp Clin Trials 2019;87:105859. [PMID: 31669450 DOI: 10.1016/j.cct.2019.105859] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
17 Khalsa JH, Mathur P. Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies. Viruses 2021;13:1363. [PMID: 34372569 DOI: 10.3390/v13071363] [Reference Citation Analysis]
18 Ryan P, Valencia J, Cuevas G, Troya J, Ramon C, Rodríguez A, Torres-Macho J, Muñoz-Gómez MJ, Canorea I, Vázquez-Morón S, Resino S. HCV screening based on dried blood samples and linkage to care in people who use drugs: A prospective study. Int J Drug Policy 2021;92:103134. [PMID: 33517130 DOI: 10.1016/j.drugpo.2021.103134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Karlsson N, Kåberg M, Berglund T, Hammarberg A, Widman L, Ekström AM. A prospective cohort study of risk behaviours, retention and loss to follow-up over 5 years among women and men in a needle exchange program in Stockholm, Sweden. Int J Drug Policy 2021;90:103059. [PMID: 33360734 DOI: 10.1016/j.drugpo.2020.103059] [Reference Citation Analysis]
20 Martínez-Pérez GZ, Nikitin DS, Bessonova A, Fajardo E, Bessonov S, Shilton S. Values and preferences for hepatitis C self-testing among people who inject drugs in Kyrgyzstan. BMC Infect Dis 2021;21:609. [PMID: 34171990 DOI: 10.1186/s12879-021-06332-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Sun HY, Cheng CY, Lin CY, Yang CJ, Lee NY, Liou BH, Tang HJ, Liu YM, Lee CY, Chen TC, Huang YC, Lee YT, Tsai MJ, Lu PL, Tsai HC, Wang NC, Hung TC, Cheng SH, Hung CC. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. World J Gastroenterol 2022; 28(11): 1172-1183 [DOI: 10.3748/wjg.v28.i11.1172] [Reference Citation Analysis]
22 Safreed-Harmon K, Blach S, Aleman S, Bollerup S, Cooke G, Dalgard O, Dillon JF, Dore GJ, Duberg AS, Grebely J, Boe Kielland K, Midgard H, Porter K, Razavi H, Tyndall M, Weis N, Lazarus JV. The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clin Infect Dis. 2019;69:2218-2227. [PMID: 31352481 DOI: 10.1093/cid/ciz714] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
23 Larney S, Madden A, Marshall AD, Martin NK, Treloar C. A gender lens is needed in hepatitis C elimination research. International Journal of Drug Policy 2022;103:103654. [DOI: 10.1016/j.drugpo.2022.103654] [Reference Citation Analysis]
24 Ouzan D, Larrey D, Guyader D, Remy AJ, Riachi G, Heluwaert F, Truchi R, Combis JM, Bailly F, Rosa I, Hézode C, Glorian-Petraud D, Libert O, Ramroth H, Asselah T, Thiefin G, Roulot D, Roche B, Leroy V, Dumortier J, Thabut D, Pol S; HELIOS study group. Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France. Dig Dis Sci 2021;66:881-98. [PMID: 32303953 DOI: 10.1007/s10620-020-06234-1] [Reference Citation Analysis]
25 Zhao Q, Jiang S, Li M, Yao L, Ma X, Li M, Wang C, Pan Y, Zhao H, Li B. Incidence trend and age-period-cohort analysis of reported hepatitis C among residents aged 30 to 79 in northeastern China, 2008 to 2017. Medicine (Baltimore) 2020;99:e22005. [PMID: 32899048 DOI: 10.1097/MD.0000000000022005] [Reference Citation Analysis]
26 Patel EU, Solomon SS, Lucas GM, McFall AM, Tomori C, Srikrishnan AK, Kumar MS, Laeyendecker O, Celentano DD, Thomas DL, Quinn TC, Mehta SH. Drug use stigma and its association with active hepatitis C virus infection and injection drug use behaviors among community-based people who inject drugs in India. Int J Drug Policy 2021;:103354. [PMID: 34247900 DOI: 10.1016/j.drugpo.2021.103354] [Reference Citation Analysis]
27 Romagnoli D. Elimination of hepatitis C virus infection in Europe: targeting the obstacles. Exploration of Medicine. [DOI: 10.37349/emed.2022.00075] [Reference Citation Analysis]
28 Valencia J, Lazarus JV, Ceballos FC, Troya J, Cuevas G, Resino S, Torres-Macho J, Ryan P. Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care. Liver Int 2021. [PMID: 34767680 DOI: 10.1111/liv.15095] [Reference Citation Analysis]
29 Norton BL, Bachhuber MA, Singh R, Agyemang L, Arnsten JH, Cunningham CO, Litwin AH. Evaluation of contingency management as a strategy to improve HCV linkage to care and treatment in persons attending needle and syringe programs: A pilot study. Int J Drug Policy 2019;69:1-7. [PMID: 31003171 DOI: 10.1016/j.drugpo.2019.02.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
30 Gutiérrez García ML, Gómez Perosanz R, Acedo Sanz JM, Delgado-Iribarren García-Campero A, Claudio Domínguez I, Domenech Gómez-Imaz A, Pérez Encinas M, de la Fuente Hermosín I, Fabero Jimenez A, Fernández Rodríguez CM. Coordinated assistance plan for the elimination of hepatitis C virus at the centro de ayuda integral al drogodependiente (CAID (Comprehensive Care Centre for Drug Addicts)). Gastroenterol Hepatol 2021;44:214-20. [PMID: 33162188 DOI: 10.1016/j.gastrohep.2020.08.002] [Reference Citation Analysis]
31 Havens JR, Schaninger T, Fraser H, Lofwall M, Staton M, Young AM, Hoven A, Walsh SL, Vickerman P. Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C. BMJ Open 2021;11:e041490. [PMID: 34226208 DOI: 10.1136/bmjopen-2020-041490] [Reference Citation Analysis]
32 Chan K, Mangla N. Prevalence and risk factors of hepatitis C virus infection in the rural northeastern United States. Ann Hepatol 2021;:100576. [PMID: 34752949 DOI: 10.1016/j.aohep.2021.100576] [Reference Citation Analysis]
33 Butsashvili M, Kamkamidze G, Kajaia M, Gvinjilia L, Kuchuloria T, Khonelidze I, Gogia M, Dolmazashvili E, Kerashvili V, Zakalashvili M, Shadaker S, Nasrullah M, Sonjelle S, Japaridze M, Averhoff F. Integration of hepatitis C treatment at harm reduction centers in Georgia-Findings from a patient satisfaction survey. Int J Drug Policy 2020;84:102893. [PMID: 32739613 DOI: 10.1016/j.drugpo.2020.102893] [Reference Citation Analysis]
34 Howard KA, Rennert L, Pericot-Valverde I, Heo M, Norton BL, Akiyama MJ, Agyemang L, Litwin AH. Utilizing patient perception of group treatment in exploring medication adherence, social support, and quality of life outcomes in people who inject drugs with hepatitis C. J Subst Abuse Treat 2021;126:108459. [PMID: 34116813 DOI: 10.1016/j.jsat.2021.108459] [Reference Citation Analysis]
35 Karlsson N, Berglund T, Ekström AM, Hammarberg A, Tammi T. Could 30 years of political controversy on needle exchange programmes in Sweden contribute to scaling-up harm reduction services in the world? Nordic Studies on Alcohol and Drugs 2021;38:66-88. [DOI: 10.1177/1455072520965013] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Torrens M, Soyemi T, Bowman D, Schatz E. Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment. BMC Infect Dis 2020;20:702. [PMID: 32972393 DOI: 10.1186/s12879-020-05426-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Høj SB, Jacka B, Minoyan N, Artenie AA, Bruneau J. Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs. Int J Drug Policy 2019;72:11-23. [PMID: 31003825 DOI: 10.1016/j.drugpo.2019.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
38 Pourmarzi D, Smirnov A, Hepworth J, Rahman T, FitzGerald G, Hall L. Elements of community-based models for treating hepatitis C virus in supporting HCV elimination in Australia: A Delphi study. Int J Health Plann Manage. 2019;34:e1247-e1256. [PMID: 30901129 DOI: 10.1002/hpm.2770] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
39 Midgard H, Finbråten AK, Malme KB, Berg-Pedersen RM, Tanum L, Olsen IC, Bjørnestad R, Dalgard O. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs. Trials 2020;21:524. [PMID: 32539853 DOI: 10.1186/s13063-020-04434-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Smith S, Harmanci H, Hutin Y, Hess S, Bulterys M, Peck R, Rewari B, Mozalevskis A, Shibeshi M, Mumba M, Le LV, Ishikawa N, Nolna D, Sereno L, Gore C, Goldberg DJ, Hutchinson S. Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017. JHEP Rep 2019;1:81-9. [PMID: 32039355 DOI: 10.1016/j.jhepr.2019.04.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
41 Rockstroh JK, Yazdanpanah Y. HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges? J Antimicrob Chemother 2019;74:v2-4. [PMID: 31782498 DOI: 10.1093/jac/dkz447] [Reference Citation Analysis]
42 Goodyear T, Ti L, Carrieri P, Small W, Knight R. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. Int J Drug Policy 2020;81:102766. [PMID: 32416525 DOI: 10.1016/j.drugpo.2020.102766] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
43 Saab S, Challita YP, Najarian LM, Guo R, Saggi SS, Choi G. Hepatitis C Screening: Barriers to Linkage to Care. J Clin Transl Hepatol. 2019;7:226-231. [PMID: 31608214 DOI: 10.14218/jcth.2018.00063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
44 Lazarus JV, Herranz A, Picchio CA, Villota-Rivas M, Rodríguez A, Alonso JM, Moratinos A, Perrotta A, Tegeo E, Bibiloni F, Buti M, Vilella À. Eliminating hepatitis C on the Balearic Islands, Spain: a protocol for an intervention study to test and link people who use drugs to treatment and care. BMJ Open 2021;11:e053394. [PMID: 34675021 DOI: 10.1136/bmjopen-2021-053394] [Reference Citation Analysis]
45 Lazarus JV, Baker L, Cascio M, Onyango D, Schatz E, Smith AC, Spinnewijn F; Nobody Left Outside initiative. Novel health systems service design checklist to improve healthcare access for marginalised, underserved communities in Europe. BMJ Open 2020;10:e035621. [PMID: 32265247 DOI: 10.1136/bmjopen-2019-035621] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
46 Picchio CA, Valencia J, Doran J, Swan T, Pastor M, Martró E, Colom J, Lazarus JV. The impact of the COVID-19 pandemic on harm reduction services in Spain. Harm Reduct J 2020;17:87. [PMID: 33143699 DOI: 10.1186/s12954-020-00432-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
47 Schwarz T, Horváth I, Fenz L, Schmutterer I, Rosian-schikuta I, Mårdh O. Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation. International Journal of Drug Policy 2022;102:103588. [DOI: 10.1016/j.drugpo.2022.103588] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]